Natixis Advisors
SYRE icon

Natixis Advisors’s Spyre Therapeutics SYRE Stock Holding History

Natixis Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,401
Closed -$265K – 1694
2025
Q1 		$265K Sell
16,401
-899
-5% -$18.7K ﹤0.01% 1565
2024
Q4 		$403K Buy
+17,300
New +$507K ﹤0.01% 1515

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Natixis Advisors's SYRE Position: Q2 2025 in Review

Natixis Advisors sold out of Spyre Therapeutics (SYRE) in Q2 2025, closing a stake of 16,401 shares — an estimated $265K sold.

Natixis Advisors first reported a position in SYRE in Q4 2024 and held it in 2 quarters. The position peaked at $403K in Q4 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q2 2025.

  • Natixis Advisors reported no remaining Spyre Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Natixis Advisors sold 16,401 Spyre Therapeutics shares in Q2 2025, an estimated $265K.
  • Natixis Advisors first reported a position in Spyre Therapeutics in Q4 2024 and held it in 2 quarters.
  • Natixis Advisors's Spyre Therapeutics position peaked at $403K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2025.

Based on Natixis Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.